Delays longer than 90 days before seeking care for breast cancer were linked to a threefold increase in two-year mortality, particularly affecting older and socially isolated patients, according to a multicenter Spanish study.
Bavarian Nordic’s freeze-dried Jynneos vaccine offers logistical advantages over the liquid-frozen version, supporting long-term U.S. stockpiling and public health preparedness.
In a recent clinical trial, researchers found that a reduced-dose chemoradiotherapy regimen for early-stage anal cancer may be comparable to standard treatment in achieving short-term tumor response, while causing fewer serious side effects.
A new review finds AI-based models more accurate than traditional regression models at predicting lung cancer risk, especially when using low-dose CT imaging data.
The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.